CN113913512A - 一种用于检测脊髓肌萎缩症相关基因的引物探针组合物及试剂盒 - Google Patents
一种用于检测脊髓肌萎缩症相关基因的引物探针组合物及试剂盒 Download PDFInfo
- Publication number
- CN113913512A CN113913512A CN202111451562.4A CN202111451562A CN113913512A CN 113913512 A CN113913512 A CN 113913512A CN 202111451562 A CN202111451562 A CN 202111451562A CN 113913512 A CN113913512 A CN 113913512A
- Authority
- CN
- China
- Prior art keywords
- kit
- primer
- probe
- seq
- smn1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000523 sample Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 title claims description 24
- 208000002320 spinal muscular atrophy Diseases 0.000 title description 15
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims abstract description 26
- 102100021947 Survival motor neuron protein Human genes 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 21
- 238000012986 modification Methods 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 238000000137 annealing Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 238000001514 detection method Methods 0.000 description 21
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 6
- 101150081851 SMN1 gene Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 101150015954 SMN2 gene Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108700011325 Modifier Genes Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710205841 Ribonuclease P protein component 3 Proteins 0.000 description 1
- 102100033795 Ribonuclease P protein subunit p30 Human genes 0.000 description 1
- 101150061589 Rpp30 gene Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 102000045921 human GAA Human genes 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229940103023 myozyme Drugs 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111451562.4A CN113913512A (zh) | 2021-12-01 | 2021-12-01 | 一种用于检测脊髓肌萎缩症相关基因的引物探针组合物及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111451562.4A CN113913512A (zh) | 2021-12-01 | 2021-12-01 | 一种用于检测脊髓肌萎缩症相关基因的引物探针组合物及试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113913512A true CN113913512A (zh) | 2022-01-11 |
Family
ID=79248523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111451562.4A Pending CN113913512A (zh) | 2021-12-01 | 2021-12-01 | 一种用于检测脊髓肌萎缩症相关基因的引物探针组合物及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113913512A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116144750A (zh) * | 2022-11-10 | 2023-05-23 | 合肥行知生物技术有限公司 | 一种引物探针组、数字pcr试剂盒及应用 |
CN117344008A (zh) * | 2023-12-05 | 2024-01-05 | 北京华瀚基因科技有限公司 | 基于2-ΔΔCt法检测SMN1基因拷贝数的试剂盒 |
WO2024085079A1 (ja) * | 2022-10-17 | 2024-04-25 | Craif株式会社 | プライマーセット、脊髄性筋萎縮症の発症及び/又は発症リスク判定キット、並びに、脊髄性筋萎縮症の発症及び/又は発症リスク判定方法。 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789440A (zh) * | 2014-02-19 | 2014-05-14 | 上海五色石医学研究有限公司 | 脊髓性肌萎缩症相关基因突变检测方法、相关检测探针组合物及检测试剂盒、以及相关应用 |
CN104630368A (zh) * | 2015-02-09 | 2015-05-20 | 上海五色石医学研究有限公司 | 一种人运动神经元基因拷贝数相对定量检测方法及试剂盒 |
CN108048548A (zh) * | 2017-11-07 | 2018-05-18 | 北京华瑞康源生物科技发展有限公司 | 人脊髓性肌萎缩症致病基因拷贝数检测荧光定量pcr试剂盒 |
CN108396060A (zh) * | 2018-03-09 | 2018-08-14 | 中南大学 | 基于实时荧光定量pcr技术的脊肌萎缩症致病基因smn1拷贝数检测试剂盒及方法 |
CN108456726A (zh) * | 2018-04-19 | 2018-08-28 | 深圳会众生物技术有限公司 | 脊髓性肌萎缩症基因检测探针、引物和试剂盒 |
CN111118151A (zh) * | 2020-03-26 | 2020-05-08 | 广东永诺医疗科技有限公司 | 基于数字pcr法的人smn1与smn2基因拷贝数检测试剂盒 |
CN112522389A (zh) * | 2020-12-21 | 2021-03-19 | 清华大学 | 一种检测脊髓性肌萎缩症数字pcr试剂盒及其应用 |
-
2021
- 2021-12-01 CN CN202111451562.4A patent/CN113913512A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103789440A (zh) * | 2014-02-19 | 2014-05-14 | 上海五色石医学研究有限公司 | 脊髓性肌萎缩症相关基因突变检测方法、相关检测探针组合物及检测试剂盒、以及相关应用 |
CN104630368A (zh) * | 2015-02-09 | 2015-05-20 | 上海五色石医学研究有限公司 | 一种人运动神经元基因拷贝数相对定量检测方法及试剂盒 |
CN108048548A (zh) * | 2017-11-07 | 2018-05-18 | 北京华瑞康源生物科技发展有限公司 | 人脊髓性肌萎缩症致病基因拷贝数检测荧光定量pcr试剂盒 |
CN108396060A (zh) * | 2018-03-09 | 2018-08-14 | 中南大学 | 基于实时荧光定量pcr技术的脊肌萎缩症致病基因smn1拷贝数检测试剂盒及方法 |
CN108456726A (zh) * | 2018-04-19 | 2018-08-28 | 深圳会众生物技术有限公司 | 脊髓性肌萎缩症基因检测探针、引物和试剂盒 |
CN111118151A (zh) * | 2020-03-26 | 2020-05-08 | 广东永诺医疗科技有限公司 | 基于数字pcr法的人smn1与smn2基因拷贝数检测试剂盒 |
CN112522389A (zh) * | 2020-12-21 | 2021-03-19 | 清华大学 | 一种检测脊髓性肌萎缩症数字pcr试剂盒及其应用 |
Non-Patent Citations (1)
Title |
---|
章印红等: "脊髓性肌萎缩症患儿SMN1和SMN2基因拷贝数与临床表型的相关性分析", 《中国当代儿科杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024085079A1 (ja) * | 2022-10-17 | 2024-04-25 | Craif株式会社 | プライマーセット、脊髄性筋萎縮症の発症及び/又は発症リスク判定キット、並びに、脊髄性筋萎縮症の発症及び/又は発症リスク判定方法。 |
CN116144750A (zh) * | 2022-11-10 | 2023-05-23 | 合肥行知生物技术有限公司 | 一种引物探针组、数字pcr试剂盒及应用 |
CN117344008A (zh) * | 2023-12-05 | 2024-01-05 | 北京华瀚基因科技有限公司 | 基于2-ΔΔCt法检测SMN1基因拷贝数的试剂盒 |
CN117344008B (zh) * | 2023-12-05 | 2024-03-08 | 北京华瀚基因科技有限公司 | 基于2-ΔΔCt法检测SMN1基因拷贝数的试剂盒 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113913512A (zh) | 一种用于检测脊髓肌萎缩症相关基因的引物探针组合物及试剂盒 | |
CN108048548A (zh) | 人脊髓性肌萎缩症致病基因拷贝数检测荧光定量pcr试剂盒 | |
CN117070607B (zh) | 一种检测人脊髓性肌萎缩症smn1和smn2基因拷贝数的荧光定量pcr试剂盒 | |
CN108026583A (zh) | Hla-b*15:02的单核苷酸多态性及其应用 | |
CN106498028B (zh) | Egfr的t790m突变的诊断方法及试剂盒 | |
WO2023279042A2 (en) | Compositions and methods for detection of severe acute respiratory syndrome coronavirus 2 variants | |
CN111534588A (zh) | 基于荧光定量pcr检测急性淋巴细胞白血病中基因突变的试剂盒及方法 | |
CN107513577A (zh) | 一种高效检测egfrt790m突变体的方法以及用于检测的探针和试剂盒 | |
CN113621704B (zh) | 肝癌的检测和诊断的试剂及试剂盒 | |
CN102925559B (zh) | 一种定量检测mpl基因w515位点突变的试剂盒 | |
TWI780315B (zh) | 量化標的基因的突變型等位基因負擔的方法 | |
CN116004775A (zh) | 一种人运动神经元拷贝数定量的引物探针组合物、试剂盒及方法 | |
WO2021082358A1 (zh) | 一种检测HTR2A基因rs6313位点的TaqMan探针实时荧光PCR方法及其引物探针组合 | |
CN115976182A (zh) | 一种检测脊髓性肌萎缩症致病基因smn1的引物探针组以及试剂盒 | |
CN113322317A (zh) | 一种用于线粒体肥胖基因突变检测的引物对和探针组及试剂盒 | |
CN114457151B (zh) | 一种用于检测苯丙氨酸羟化酶基因突变的检测试剂盒及其检测方法 | |
CN111593115A (zh) | 用于β-地中海贫血基因突变多重实时荧光PCR检测的引物和探针组合及试剂盒 | |
CN110923312A (zh) | 一种检测CYP1A2基因rs762551位点的实时荧光PCR方法及其引物探针组合 | |
CN117802223B (zh) | 基于2-δδct方法检测smn1基因和smn2基因拷贝数的试剂盒及其使用方法 | |
CN114606311B (zh) | SLC39A13基因rs755555位点的应用及其检测引物和探针组合、试剂盒 | |
CN113265461B (zh) | 一种用于检测高频基因致病变异的引物组和探针组及试剂盒 | |
JP2002238577A (ja) | 脳動脈瘤感受性遺伝子 | |
CN108753961B (zh) | Braf v600e基因突变检测引物、方法及试剂盒 | |
KR101889072B1 (ko) | 디지털 PCR을 이용한 유전성 강직성 대마비(Hereditary spastic paraplegia, HSP) 관련 유전자 SPG4의 거대결손 검증법 | |
CN111363799A (zh) | 一种vps39基因k87r突变检测的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220616 Address after: 215000 South Building A3, biomedical industrial park, No. 218, Xinghu street, Suzhou Industrial Park, Jiangsu Province Applicant after: SUZHOU BASECARE MEDICAL DEVICE Co.,Ltd. Address before: 250100 No. 27 South Grand Road, Shandong, Ji'nan Applicant before: SHANDONG University |
|
TA01 | Transfer of patent application right | ||
CB02 | Change of applicant information |
Address after: 215000 unit 101, A3 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Jiangsu Province Applicant after: SUZHOU BASECARE MEDICAL DEVICE Co.,Ltd. Address before: 215000 South Building A3, biomedical industrial park, No. 218, Xinghu street, Suzhou Industrial Park, Jiangsu Province Applicant before: SUZHOU BASECARE MEDICAL DEVICE Co.,Ltd. |
|
CB02 | Change of applicant information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220111 |
|
RJ01 | Rejection of invention patent application after publication |